XBiotech Inc. (XBIT) · Oct 26, 2026 · Exec change

XBiotech executive change formalizes Co-CEO role with 2M options

Co-CEO agreement — $150,000 base salary; 2,000,000 options vesting over three years

XBiotech’s executive change is now formal: Jan-Paul Simard gets a $150,000 base salary and 2 million stock options as Co-CEO.

XBiotech is a development-stage biotechnology company advancing its True Human antibody pipeline, including oncology and inflammatory-disease programs, with recent Phase II activity in colorectal cancer and axial spondyloarthritis. This filing formalizes a leadership change that was already public. The company had announced on October 23, 2026 that Jan-Paul Simard would serve as Co-CEO alongside Sushma Shivaswamy, so the appointment itself is not a fresh surprise. The new agreement makes the arrangement contractual and assigns Simard strategic and operational responsibilities alongside Shivaswamy. 〔0〕 The new information is the compensation and incentive structure. Simard receives a $150,000 annual base salary, prorated for 2026, plus 2,000,000 options priced at the October 26 closing share price. 〔1〕 〔2〕 The option grant creates a real but unquantified dilution overhang. The options vest in six equal installments over three years, aligning Simard with execution of the clinical pipeline but potentially increasing future share dilution; the filing does not state the grant as a percentage of shares outstanding. Bottom line: This is mainly the contractual completion of a leadership transition already disclosed, not a new strategic pivot. It adds execution incentives but also a sizeable option grant, leaving the business impact dependent on whether the shared leadership structure advances XBiotech’s clinical programs.**

What to watch next

Clinical execution under the new co-CEO structure

Original filing on SEC EDGAR

XBiotech executive change formalizes Co-CEO role with 2M options | XBIT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.